CML

(redirected from chronic myelocytic leukemia)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to chronic myelocytic leukemia: myelogenous, chronic granulocytic leukemia

CML

Capital Market Line

In the capital asset pricing model, a line that plots the extra return an investor expects for each change in the level of risk. Rational investors expect higher returns for riskier assets and the capital market line shows this graphically. A portfolio that accurately reflects the capital market line is considered a Markowitz efficient portfolio. The slope of the capital market line is a calculation of the equilibrium market price of risk. See also: Beta.
References in periodicals archive ?
Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of route of administration and molecule type.
Development of multiple myeloma in a patient with chronic myelocytic leukemia after treatment with imatinib mesylate.
Companies Involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Development
Coverage of the Chronic Myelocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
This product represents a new dosage form and strength of an antineoplastic agent used in the treatment of melanoma, resistant chronic myelocytic leukemia, recurrent, metastatic, or inoperable carcinoma of the ovary, and certain head and neck cancers.
Colon, renal cell carcinoma, hepatoma, phepochromocytoma, non-small cell lung cancer, primitive neuroectodermal tumours, meningiomas, gliomas, chronic myelocytic leukemia, chronic lymphocytic leukemia, Kaposi's sarcoma.
Significant tumor response to Hydroxyurea has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary.
HYDREA is an anti- tumor agent currently indicated for use in treating melanoma, chronic myelocytic leukemia and ovarian cancer.

Full browser ?